<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tiopronin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tiopronin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tiopronin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10287" href="/d/html/10287.html" rel="external">see "Tiopronin: Drug information"</a> and <a class="drug drug_patient" data-topicid="12137" href="/d/html/12137.html" rel="external">see "Tiopronin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F228218"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Thiola;</li>
<li>Thiola EC</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1039207"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Urinary Tract Product</span></li></ul></div>
<div class="block dop drugH1Div" id="F12595418"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9eeed915-d2d8-4f5e-9a8c-8d0cacea8cae">Prevention of nephrolithiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of nephrolithiasis (cystine):</b> Limited data available in patients weighing &lt;20 kg: <b>Note: </b>Use in combination with high fluid intake, alkali, and diet modification; consider initiating at lower doses in patients with a history of severe toxicity to d-penicillamine:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Immediate-release tablet (eg, Thiola), delayed-release tablets (eg, Thiola EC): Oral: Initial: 15 mg/kg/day in 3 divided doses; titrate dose to reduce urinary cysteine level to &lt;250 mg/L. Maximum daily dose: 50 mg/kg/<b>day</b>. In one trial, patients with cystinuria (n=18, ages: 1.8 to 24 years), 16 patients received tiopronin in combination with urinary alkalinization to prevent nephrolithiasis or reduce size of current stones. Mean dose required was 24.65 mg/kg/day (range: 13.8 to 51 mg/kg/day). Older children required lower mg/kg dosing than younger (smaller) children. Stone episodes decreased from 0.28 per year to 0.03 per year and several had reductions in size and number of pre-existing stones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17694338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17694338'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Proteinuria: Discontinue tiopronin in patients who develop proteinuria; once proteinuria resolves, consider resuming at a lower dose.</p></div>
<div class="block dorp drugH1Div" id="F53373509"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage recommendations provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F53373510"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage recommendations provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F228220"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10287" href="/d/html/10287.html" rel="external">see "Tiopronin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9eeed915-d2d8-4f5e-9a8c-8d0cacea8cae">Prevention of nephrolithiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of nephrolithiasis (cystine):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 800 mg/day in 3 divided doses; average dose: 1,000 mg/day. Consider a lower initial dose in patients with history of severe toxicity to d-penicillamine.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: Adjust dose to reduce urinary cystine level to &lt;250 mg/L.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F12595320"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (12% to 25%), oral mucosa ulcer (12% to 18%), diarrhea (6% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (12%), asthenia (4% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (6%), peripheral edema (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (8%), ecchymoses (6%), wrinkling of skin (6%), pruritus (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (10%), anorexia (8%), abdominal pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (6% to 10%), impotence (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Abdominal distension, abdominal distress, ageusia, back pain, burning sensation, cardiac failure, cheilosis, decreased appetite, decreased estimated GFR (eGFR), dehydration, dermatologic disorders (abnormal skin texture), dizziness, dysgeusia, dyspepsia, eructation, flank pain, flatulence, gastroesophageal reflux disease, gastrointestinal disease, headache, hyperhidrosis, hypersensitivity reaction, hypoesthesia, increased serum transaminases, jaundice, joint swelling, limb pain, malaise, membranous glomerulonephritis, musculoskeletal pain, myalgia, neck pain, nephrotic syndrome, pain, pemphigus foliaceus, renal failure syndrome, skin irritation, swelling, vertigo, weight gain, xeroderma, xerostomia</p></div>
<div class="block coi drugH1Div" id="F12593125"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tiopronin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F12593745"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Goodpasture syndrome: Tiopronin is structurally similar to penicillamine. Penicillamine has rarely been associated with fatalities due to Goodpasture syndrome; therefore, the potential of Goodpasture syndrome in tiopronin-treated patients is possible; discontinue therapy if signs or symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Tiopronin is structurally similar to penicillamine. Penicillamine has been associated with hematologic toxicities. Signs of toxicity include leukopenia without eosinophilia and thrombocytopenia. Advise patients to report early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, or petechial or purpuric hemorrhage. Therapy should be discontinued if platelet count falls to &lt;100,000/mm<sup>3</sup> or WBC &lt;3,500/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (drug fever, rash, fever, arthralgia, and lymphadenopathy) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Tiopronin is structurally similar to penicillamine. Penicillamine has rarely been associated with fatalities due to myasthenia gravis; therefore, the potential of myasthenia gravis in tiopronin-treated patients is possible; discontinue therapy if signs or symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pemphigus: Tiopronin is structurally similar to penicillamine. Penicillamine has been associated with pemphigus. Discontinue treatment if pemphigus-type reactions occur; additional therapy may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proteinuria: Proteinuria, including nephrotic syndrome and membranous nephropathy, have been reported. Risk may be increased in pediatric patients receiving &gt;50 mg/kg/day. Monitor for the development of proteinuria; interrupt therapy in patients who develop proteinuria.</p></div>
<div class="block foc drugH1Div" id="F228213"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thiola: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thiola EC: 100 mg, 300 mg</p></div>
<div class="block geq drugH1Div" id="F228205"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F5574863"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Thiola EC Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $33.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $101.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Thiola Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $33.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tiopronin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $32.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613935"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: High daily fluid intake should continue while taking tiopronin.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release (eg, Thiola): Administer 1 hour before or 2 hours after meals; administer at the same times each day.</p>
<p style="text-indent:-2em;margin-left:2em;">Delayed release (eg, Thiola EC): Administer with or without food; however, it is recommended to be consistent with regards to meals. For patients unable to swallow tablet whole, tablet may be crushed and mixed with applesauce; administration with other liquids or foods is not recommended (has not been studied). Crush 1 tablet at a time (in a pill crusher or with mortar and pestle); mix crushed tablet with ~1 tablespoonful of applesauce until powder is well dispersed. Administer mixture immediately (or mixture may be stored in refrigerator for ≤2 hours). Add tap water to any leftover applesauce mixture remaining in the container and have patient consume.</p></div>
<div class="block adm drugH1Div" id="F12595443"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Delayed release tablets: Administer consistently with or without regard to meals. For patients unable to swallow tablet whole, tablet may be crushed and mixed with applesauce; administration with other liquids or foods is not recommended (has not been studied). Crush 1 tablet at a time (in a pill crusher or mortar and pestle) and mix with ~1 tablespoonful of applesauce until powder is well dispersed. Administer mixture immediately (or mixture may be stored in refrigerator for ≤2 hours). To ensure applesauce mixture is consumed, add tap water to the mixture container, mix, and have patient drink the water.</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablets: Administer 1 hour before or 2 hours after meals.</p></div>
<div class="block sts drugH1Div" id="F12595409"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53569149"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of kidney stone (cystine) formation in patients with severe homozygous cystinuria who are resistant to treatment with high fluid intake, alkali, and diet modification (Tablets: Immediate release, Delayed release: FDA approved in pediatric patients ≥20 kg [age not specified] and adults).</p></div>
<div class="block cyt drugH1Div" id="F13300144"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223334"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May increase the bioavailability of Tiopronin.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F53458825"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Tiopronin is released faster from delayed-release tablets in the presence of alcohol, and the risk for adverse events when taken with alcohol is unknown. Management: Avoid alcohol 2 hours before and 3 hours after taking delayed-release tablets.</p></div>
<div class="block dic drugH1Div" id="F12595442"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">IR tablets should be taken 1 hour before or 2 hours after meals. Tiopronin EC can be taken with or without food; however, it is important to keep consistency with regard to food.</p></div>
<div class="block pri drugH1Div" id="F12593115"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53569136"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function, 24-hour urinary protein (baseline), development of proteinuria every 3 to 6 months (eg, 24-hour urinary protein, urinalysis), urinary cystine 1 month after treatment begins, then every 3 months; monitor for stone formation (eg, x-ray, ultrasound).</p></div>
<div class="block pha drugH1Div" id="F12595410"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As an active reducing agent, tiopronin undergoes thiol-disulfide exchange with cystine to form tiopronin-cystine disulfide, which is more water soluble than cystine. As a result, the amount of sparingly soluble cystine in the urine is decreased and the formation of cystine calculi is reduced.</p></div>
<div class="block phk drugH1Div" id="F53463500"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Delayed release tablets: C<sub>max</sub> and AUC increased by 38% and 14%, respectively, when administered crushed in applesauce compared to intact tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed release (intact tablets): 3 hours (median) (range: 1 to 6 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed release (crushed; mixed in applesauce): 1 hour (median) (range: 0.5 to 2 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: 1 hour (median) (range: 0.5 to 2.1 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (48% within 4 hours; 78% within 72 hours).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F228216"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Captimer | Thiola</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tetoprosin | Thiola</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Acadione | Captimer | Thiola</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acadione</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Thiola</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Igeniuan | Stargen | Thiola</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11214766">
<a name="11214766"></a>Akrivis C, Vezyraki P, Kiortsis DN, Fotopoulos A, Evangelou A. Inhibition of puerperal lactation with 2-mercaptopropionyl-glycine. <i>Eur J Clin Pharmacol</i>. 2000;56(9-10):621-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tiopronin-pediatric-drug-information/abstract-text/11214766/pubmed" id="11214766" target="_blank">11214766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17694338">
<a name="17694338"></a>Dello Strologo L, Laurenzi C, Legato A, Pastore A. Cystinuria in children and young adults: success of monitoring free-cystine urine levels. <i>Pediatr Nephrol</i>. 2007;22(11):1869-1873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tiopronin-pediatric-drug-information/abstract-text/17694338/pubmed" id="17694338" target="_blank">17694338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3534301">
<a name="3534301"></a>Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercatopropionylglycine. <i>J Urol</i>. 1986;136(5):1003-1008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tiopronin-pediatric-drug-information/abstract-text/3534301/pubmed" id="3534301" target="_blank">3534301</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pearle MS, Goldfarb DS, Assimos DG, et al. Medical Management of Kidney Stones: AUA Guideline. 2014. http://www.auanet.org/common/pdf/education/clinical-guidance/Medical-Management-of-Kidney-Stones.pdf. Accessed September 4, 2014.</div>
</li>
<li>
<div class="reference">
                  Thiola (tiopronin) [prescribing information]. San Antonio, TX: Mission Pharmacal; January 2021.</div>
</li>
<li>
<div class="reference">
                  Thiola (tiopronin) [prescribing information]. San Antonio, TX: Mission Pharmacal; June 2019.</div>
</li>
<li>
<div class="reference">
                  Thiola EC (tiopronin) [prescribing information]. San Antonio, TX: Mission Pharmacal; March 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 121955 Version 44.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
